This has led to the discovery of dozens of TAAs associated with GBM, such as CTCFL, ACTL8, TERT, WT-1, OIP5, XAGE3, IL-13Rα2, EGFR vIII, IL-4, gp100, survivin, MAGE-1, CD133, TRP-2, AIM-2, HER2, EphA2, and YKL-40, which have been evaluated in early-stage therapeutic preclinical trials to show their safety and immunogenicity in the human body [53–55]. The gene discussed is BIRC5; the disease is glioblastoma.